Nanoemulsified Butenafine for Enhanced Performance against Experimental Cutaneous Leishmaniasis [PDF]
Journal of Immunology Research, 2021 The production of ergosterol lipid involves the activity of different enzymes and is a crucial event for the Leishmania membrane homeostasis. Such enzymes can be blocked by azoles and allylamines drugs, such as the antifungal butenafine chloride.
Adriana Bezerra-Souza +5 more
doaj +9 more sources
Efficacy of oleylphosphocholine in experimental cutaneous leishmaniasis. [PDF]
J Antimicrob Chemother, 2023 Abstract Objectives Cutaneous leishmaniasis (CL) is a neglected tropical disease causing a range of skin lesions for which safe and efficacious drugs are lacking. Oleylphosphocholine (OLPC) is structurally similar to miltefosine and has previously demonstrated potent activity against visceral ...
Van Bocxlaer K +8 more
europepmc +4 more sources
Activity of Amphotericin B-Loaded Chitosan Nanoparticles against Experimental Cutaneous Leishmaniasis [PDF]
Molecules, 2020 Chitosan nanoparticles have gained attention as drug delivery systems (DDS) in the medical field as they are both biodegradable and biocompatible with reported antimicrobial and anti-leishmanial activities.
Alaa Riezk +4 more
doaj +2 more sources
Efficacy of Paromomycin-Chloroquine Combination Therapy in Experimental Cutaneous Leishmaniasis. [PDF]
Antimicrob Agents Chemother, 2017 ABSTRACT The 4-aminoquinoline chloroquine (CQ) is clinically used in combination with doxycycline to cure chronic Q fever, as it enhances the activity of the antibiotic against the causative bacterium Coxiella burnetii residing within macrophage phagolysosomes.
Wijnant GJ +4 more
europepmc +5 more sources
Immunomodulation From Moderate Exercise Promotes Control of Experimental Cutaneous Leishmaniasis [PDF]
Frontiers in Cellular and Infection Microbiology, 2019 Physical exercise has been described as an important tool in the prevention and treatment of numerous diseases as it promotes a range of responses and adaptations in several biological systems, including the immune system.
Rodrigo Terra +7 more
doaj +2 more sources
INFLUENCE OF MICROBIOTA IN EXPERIMENTAL CUTANEOUS LEISHMANIASIS IN SWISS MICE [PDF]
Revista do Instituto de Medicina Tropical de São Paulo, 1999 Infection of Swiss/NIH mice with Leishmania major was compared with infection in isogenic resistant C57BL/6 and susceptible BALB/c mice. Swiss/NIH mice showed self-controlled lesions in the injected foot pad. The production of high levels of interferon-g
OLIVEIRA Marcia Rosa de +5 more
doaj +4 more sources
CD4+ T cell subsets in experimental cutaneous leishmaniasis [PDF]
Memorias do Instituto Oswaldo Cruz, 1988 Phillip Scott +4 more
doaj +4 more sources
Novel benzoxaborole, nitroimidazole and aminopyrazoles with activity against experimental cutaneous leishmaniasis. [PDF]
Int J Parasitol Drugs Drug Resist, 2019 Van Bocxlaer K +11 more
europepmc +2 more sources
Microemulsion based on methyl 3,4,5-trihydroxybenzoate for the topical treatment of cutaneous leishmaniasis: an in vivo assay [PDF]
Acta Amazonica, 2023 Cutaneous leishmaniasis, caused by protozoa of the genus Leishmania, presents diverse clinical manifestations, and current therapeutic options have limitations, including long treatment periods, potential hospitalization, and excessive pain during ...
Thiago de Jesus BACHA +8 more
doaj +1 more source
Materials & Design, 2021 Leishmaniasis is a tropical disease caused by parasites of the genus Leishmania spp; it presents different clinical manifestations, of which cutaneous leishmaniasis is the most common form, and it is endemic in more than 70 countries worldwide. Only four
Jorge Higuita-Castro +6 more
doaj +1 more source